Acta Oncologica
Acta Oncologica (Acta Oncol.) is an oncology journal owned by the Acta Oncologica Foundation and now published by Medical Journals Sweden AB. Its lineage begins in 1963 and it has carried its present name since 1987, making it the oldest specialist oncology title in the Nordic countries. It became fully gold open access and moved to continuous publication in 2024, and had a 2025 impact factor of 2.7.《肿瘤学报》（Acta Oncologica''''，缩写 Acta Oncol.''）是（Acta Oncologica Foundation）所有、现由（Medical Journals Sweden AB）出版的肿瘤学期刊，脉络始于 1963 年、1987 年起用现名，是北欧地区历史最久的肿瘤学专业刊物。该刊 2024 年起转为完全金色开放获取并改为连续出版，二〇二五年影响因子为 2.7。
Scope
The journal defines itself by covering the whole oncological chain rather than a single link: population-level epidemiology and prevention at one end, translational laboratory work in the middle, and clinical diagnosis, treatment, rehabilitation and palliative care at the other, with any study in humans eligible for consideration. Its principal areas are:本刊的定位是覆盖肿瘤学的完整链条，而非只取某一环节：从人群层面的流行病学与预防，到实验室的转化研究，再到临床的诊断、治疗、康复与姑息，凡以人体为对象的研究均在本刊考虑之列。收文重点包括：
- Epidemiology and prevention: population studies of cancer incidence and mortality, risk factors and screening strategy, and vaccination and primary prevention.流行病学与预防： 癌症发病率与死亡率的人群研究、危险因素与筛查策略、疫苗接种与一级预防。
- Translational oncology and tumour immunology: molecular classification and biomarkers, the tumour microenvironment, and the mechanisms of immunotherapy and of resistance to it.转化肿瘤学与肿瘤免疫： 分子分型与生物标志物、肿瘤微环境、免疫治疗机制与耐药研究。
- Diagnosis and precision medicine: imaging and pathological diagnosis, liquid biopsy and molecular testing, and individualised treatment decisions based on tumour classification.诊断与精准医学： 影像与病理诊断、液体活检与分子检测、基于分型的个体化治疗决策。
- Medical oncology and drug treatment: clinical trials of chemotherapy, targeted agents and endocrine therapy, together with drug safety and real-world treatment studies.内科肿瘤学与药物治疗： 化疗、靶向与内分泌治疗的临床试验，药物安全性与真实世界用药研究。
- Radiotherapy and radiation physics: radiotherapy technique and dosimetry, radiation physics and treatment planning optimisation, and normal-tissue injury and protection.放射治疗与放射物理： 放疗技术与剂量学、放射物理与计划优化、正常组织损伤与防护。
- Psychosocial oncology and palliative care: patient-reported outcomes, long-term follow-up of survivors, psychosocial intervention, and rehabilitation and palliative care.心理社会肿瘤学与姑息： 患者报告结局、生存者长期随访、心理社会干预、康复与姑息治疗。
All papers have been published gold open access since January 2024 under a Creative Commons attribution licence by default, with automatic deposition in PubMed Central. The journal publishes neither an acceptance rate nor a review duration.本刊自 2024 年 1 月起全部论文以金色开放获取发表，默认许可为署名方式，论文同时自动存入（PubMed Central）；期刊不公布录用比例与审稿时长。[1]
History
- Split from radiology (1963): the lineage begins in 1963, when the parent Acta Radiologica divided into therapy, physics and biology sections从放射学分出（1963年）： 本刊脉络起于 1963 年，母刊《放射学报》在该年分为治疗物理生物三个分册，其中《放射学报：治疗、物理与生物学》即为本刊的直接前身，创刊时仍属放射学刊系。 the therapy, physics and biology section is the journal's direct predecessor, and at its start the title still belonged to the radiology family.[2]
- Two renamings and independence (1978–1987): the title became Acta Radiologica: Oncology, Radiation, Physics, Biology in 1978 and was shortened to Acta Radiologica: Oncology in 1980两次改名与独立成刊（1978—1987年）： 1978 年改称《放射学报：肿瘤学、放射、物理与生物学》，1980 年缩短为《放射学报：肿瘤学》，1987 年起彻底脱离放射学刊名，启用现名《肿瘤学报》，自此成为独立的肿瘤学刊物。 in 1987 it dropped the radiological name altogether and took its present title, from which point it has stood as an independent oncology journal.[3]
- Move to full open access (2024): from January 2024 every paper has appeared gold open access, by default under an attribution licence with a non-commercial option, with automatic deposition in PubMed Central转为完全开放获取（2024年）： 2024 年 1 月起本刊全部论文改为金色开放获取，默认采用署名许可、作者亦可选非商业性许可，论文自动存入（PubMed Central），开放获取比例由混合状态升至近乎百分之百。 the open access share rose from hybrid levels to close to one hundred per cent.[1]
- Change of publisher and continuous publication (2024): in 2024 publication passed from Informa Healthcare, part of Taylor & Francis, to the Swedish house Medical Journals Sweden AB, with the backfile remaining on the former publisher's platform出版方更替与连续出版（2024年）： 2024 年出版方由（Taylor & Francis）旗下（Informa Healthcare）换为瑞典的（Medical Journals Sweden AB），过刊仍留在原出版方平台；同年本刊取消每年八期的期号制，改为连续出版。 in the same year the journal abandoned eight issues a year in favour of continuous publication.[1]
- Metrics and indexing: the 2025 impact factor is 2.7 with a five-year figure of 2.8 and a CiteScore of 3.9指标与收录： 2025 年影响因子 2.7、五年影响因子 2.8，引用分数 3.9；本刊被科学引文索引扩展版、Scopus、MEDLINE 与（DOAJ）收录。 the journal is indexed in the Science Citation Index Expanded, Scopus, MEDLINE and the Directory of Open Access Journals.[4]
Editors
The editor-in-chief is appointed by the foundation, with the editorial office based at Lund University and Skåne University Hospital. The board is drawn mainly from Nordic oncologists with additional members from elsewhere in Europe, and editorial business is tied to the foundation's annual scientific programme.本刊由基金会聘任主编，编辑部设在隆德大学与（Skåne）大学医院，编委以北欧肿瘤学者为主并吸纳欧洲其他地区的专家，编辑事务与基金会的年度学术活动相互衔接。[5]
- Present editor-in-chief: Mef Nilbert holds the chair. She is professor of oncology in the Department of Clinical Sciences at Lund University and at the oncology clinic of Skåne University Hospital, working on the molecular epidemiology of gastrointestinal cancer现任主编： （Mef Nilbert）任主编，学术身份为隆德大学临床科学研究所、（Skåne）大学医院肿瘤科的肿瘤学教授，研究领域为胃肠道肿瘤的分子流行病学；出版方未公布其就任年份。 the publisher does not state the year of her appointment.[5]
- Composition of the office: the board is organised by tumour site and discipline, with advisory editors in statistics and bioinformatics, reflecting the journal's long-standing reliance on epidemiological and population research methods.编辑部构成： 编委会按肿瘤部位与学科方向分设编委，另设统计学与生物信息学方向的咨询编辑，反映本刊对流行病学与人群研究方法的长期倚重。[5]
- Role in the field: the journal has long been the principal venue in which Nordic oncologists publish population studies and clinical trial results, and its tradition of registry-based research gives it a documentary value in cancer epidemiology that is hard to replace.学科角色： 本刊长期是北欧肿瘤学界发表人群研究与临床试验结果的主要园地，其登记数据研究传统使本刊在肿瘤流行病学方向具有不可替代的文献价值。[1]